PL3182975T3 - Tabletki o wysokiej mocy dawki rukaparybu - Google Patents

Tabletki o wysokiej mocy dawki rukaparybu

Info

Publication number
PL3182975T3
PL3182975T3 PL15833096.9T PL15833096T PL3182975T3 PL 3182975 T3 PL3182975 T3 PL 3182975T3 PL 15833096 T PL15833096 T PL 15833096T PL 3182975 T3 PL3182975 T3 PL 3182975T3
Authority
PL
Poland
Prior art keywords
rucaparib
high dosage
dosage strength
strength tablets
tablets
Prior art date
Application number
PL15833096.9T
Other languages
English (en)
Polish (pl)
Inventor
Jeffrey Etter
Original Assignee
Pharma& Schweiz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma& Schweiz Gmbh filed Critical Pharma& Schweiz Gmbh
Publication of PL3182975T3 publication Critical patent/PL3182975T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL15833096.9T 2014-08-22 2015-08-17 Tabletki o wysokiej mocy dawki rukaparybu PL3182975T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462040849P 2014-08-22 2014-08-22
US201562101739P 2015-01-09 2015-01-09
PCT/US2015/045522 WO2016028689A1 (en) 2014-08-22 2015-08-17 High dosage strength tablets of rucaparib

Publications (1)

Publication Number Publication Date
PL3182975T3 true PL3182975T3 (pl) 2026-02-23

Family

ID=55347324

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15833096.9T PL3182975T3 (pl) 2014-08-22 2015-08-17 Tabletki o wysokiej mocy dawki rukaparybu

Country Status (23)

Country Link
US (3) US9987285B2 (enExample)
EP (1) EP3182975B1 (enExample)
JP (3) JP6574477B2 (enExample)
KR (2) KR20170043597A (enExample)
CN (2) CN106794185A (enExample)
AU (2) AU2015305696B2 (enExample)
BR (1) BR112017000865A2 (enExample)
CA (1) CA2955495C (enExample)
DK (1) DK3182975T3 (enExample)
ES (1) ES3048688T3 (enExample)
FI (1) FI3182975T3 (enExample)
HR (1) HRP20251484T1 (enExample)
IL (1) IL249946B (enExample)
LT (1) LT3182975T (enExample)
MX (1) MX367260B (enExample)
NZ (1) NZ728392A (enExample)
PL (1) PL3182975T3 (enExample)
PT (1) PT3182975T (enExample)
RS (1) RS67356B1 (enExample)
RU (1) RU2705156C2 (enExample)
SG (1) SG11201700265VA (enExample)
SI (1) SI3182975T1 (enExample)
WO (1) WO2016028689A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
HK1232218A1 (zh) 2014-02-05 2018-01-05 Merck Sharp & Dohme Llc Cgrp-活性化合物的片剂制剂
DK3182975T3 (da) * 2014-08-22 2025-10-20 Pharma& Schweiz Gmbh Tabletter med høj doseringsstyrke af rucaparib
CN106008530B (zh) * 2016-07-24 2018-06-26 石家庄久正生物科技有限公司 一种抗卵巢癌药物Rucaparib关键中间体的制备方法
CN108201534A (zh) * 2016-12-16 2018-06-26 苏州苏融生物医药有限公司 一种瑞卡帕布口服缓控释药物组合物及其用途
ES2985767T3 (es) 2017-01-24 2024-11-07 Assia Chem Ind Ltd Formas en estado sólido de rucaparib y de sales de rucaparib
EP3600314A1 (en) 2017-03-27 2020-02-05 Tesaro, Inc. Niraparib compositions
CA3076907A1 (en) 2017-09-26 2019-04-04 Tesaro, Inc. Niraparib formulations
WO2019130229A1 (en) 2017-12-28 2019-07-04 Mylan Laboratories Ltd Methods and intermediates for preparing rucaparib
KR20200121800A (ko) 2018-01-05 2020-10-26 싸이브렉사 1, 인크. 산성 또는 저산소성 질환에 걸린 조직에 관련된 질환의 치료를 위한 화합물, 조성물 및 방법
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
US12090148B2 (en) 2020-07-29 2024-09-17 Allergan Pharmaceuticals International Limited Treatment of migraine
CN109111454A (zh) * 2018-08-01 2019-01-01 宁波金未生物科技有限公司 一种瑞卡帕布s-樟脑磺酸盐
CN108853030B (zh) * 2018-09-26 2021-10-01 上海朝晖药业有限公司 一种治疗恶性肿瘤的药物制剂及其制备方法
CN111542527A (zh) * 2018-12-06 2020-08-14 上海诚妙医药科技有限公司 芦卡帕利樟脑磺酸盐的新晶型和制备方法及其用途
MY209459A (en) 2019-07-10 2025-07-09 Cybrexa 3 Inc Peptide conjugates of microtubule-targeting agents as therapeutics
CA3146560A1 (en) 2019-07-10 2021-01-14 Cybrexa 2, Inc. Peptide conjugates of cytotoxins as therapeutics
KR20230002487A (ko) 2020-04-28 2023-01-05 리젠 파마슈티컬스 아게 폴리(adp-리보스) 폴리머라제(parp) 억제제로서 유용한 신규 화합물
HRP20251324T1 (hr) 2020-07-14 2025-12-05 Assia Chemical Industries Ltd. Oblici soli rukapariba u krutom stanju
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
WO2022140537A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine
BR112023020615A2 (pt) 2021-04-08 2023-12-19 Incozen Therapeutics Pvt Ltd Inibidores de poli(adp-ribose) polimerase
AU2022353124A1 (en) 2021-09-27 2024-04-11 Allergan Pharmaceuticals International Limited Combination comprising atogepant for treating migraine
US11738029B2 (en) * 2021-11-10 2023-08-29 Crititech, Inc. Rucaparib particles and uses thereof
US20250223295A1 (en) 2022-01-11 2025-07-10 Assia Chemical Industries Ltd. Solid state forms of rucaparib tosylate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20010573B1 (en) 1999-01-11 2006-04-30 Agouron Pharmaceuticals Tricyclic inhibitors of poly(adp-ribose) polymerases
CA2520997A1 (en) 2003-03-31 2004-10-14 Stacie Sara Canan-Koch Salts of tricyclic inhibitors of poly(adp-ribose) polymerases
ATE454893T1 (de) 2003-07-25 2010-01-15 Cancer Rec Tech Ltd Tricyclische parp-hemmer
JP2008513436A (ja) 2004-09-22 2008-05-01 ファイザー・インク 8−フルオロ−2−{4−[(メチルアミノ)メチル]フェニル}−1,3,4,5−テトラヒドロ−6h−アゼピノ[5,4,3−cd]インドール−6−オンのリン酸塩の多形性及び非晶質形態
PL1794163T3 (pl) 2004-09-22 2010-06-30 Pfizer Sposób wytwarzania inhibitorów poli(adp-rybozo)polimerazy
JP2008513435A (ja) 2004-09-22 2008-05-01 ファイザー・インク ポリ(adp−リボース)ポリメラーゼ阻害剤を含む治療用組成物
CA2720744A1 (en) * 2008-04-09 2009-10-15 Lek Pharmaceuticals D.D. Granulation of active pharmaceutical ingredients
RS55487B2 (sr) 2010-02-12 2024-06-28 Pfizer Soli i polimorfi 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4,3-cd]indol-6-ona
PT2833973T (pt) 2012-04-05 2017-12-21 Vertex Pharma Compostos úteis como inibidores da cinase atr e terapias de combinação dos mesmos
DK3182975T3 (da) 2014-08-22 2025-10-20 Pharma& Schweiz Gmbh Tabletter med høj doseringsstyrke af rucaparib

Also Published As

Publication number Publication date
CA2955495C (en) 2023-09-19
MX2017001540A (es) 2017-05-11
JP6574477B2 (ja) 2019-09-11
EP3182975B1 (en) 2025-10-01
SI3182975T1 (sl) 2025-12-31
ES3048688T3 (en) 2025-12-11
RU2017109139A (ru) 2018-09-24
RS67356B1 (sr) 2025-11-28
US20180200260A1 (en) 2018-07-19
EP3182975A4 (en) 2018-04-18
KR102803917B1 (ko) 2025-05-07
NZ728392A (en) 2023-06-30
AU2015305696B2 (en) 2019-08-29
RU2017109139A3 (enExample) 2019-03-06
CN106794185A (zh) 2017-05-31
SG11201700265VA (en) 2017-02-27
LT3182975T (lt) 2025-11-25
JP2020002149A (ja) 2020-01-09
IL249946A0 (en) 2017-03-30
WO2016028689A1 (en) 2016-02-25
US10130636B2 (en) 2018-11-20
CA2955495A1 (en) 2016-02-25
AU2019272064B2 (en) 2021-11-18
KR20170043597A (ko) 2017-04-21
MX367260B (es) 2019-08-12
BR112017000865A2 (pt) 2017-12-05
JP2021038242A (ja) 2021-03-11
PT3182975T (pt) 2025-10-28
US20190099430A1 (en) 2019-04-04
AU2019272064A1 (en) 2019-12-19
FI3182975T3 (fi) 2025-11-13
CN113209033A (zh) 2021-08-06
JP7127101B2 (ja) 2022-08-29
EP3182975A1 (en) 2017-06-28
HRP20251484T1 (hr) 2026-01-02
AU2015305696A1 (en) 2017-02-02
DK3182975T3 (da) 2025-10-20
IL249946B (en) 2020-05-31
US20160051561A1 (en) 2016-02-25
JP6797980B2 (ja) 2020-12-09
RU2705156C2 (ru) 2019-11-05
US9987285B2 (en) 2018-06-05
KR20230097211A (ko) 2023-06-30
JP2017525712A (ja) 2017-09-07

Similar Documents

Publication Publication Date Title
IL287437A (en) Flavociclib solid dosage forms
IL249946A0 (en) High Dose Strength Rocaprib Tablets
IL270954A (en) Pharmaceutical compounds
GB201404922D0 (en) Pharmaceutical compounds
SG11201702298VA (en) Pharmaceutical preparation
GB201416513D0 (en) Pharmaceutical compounds
IL246613B (en) Dosing regimen of iron trimaltol
GB201417707D0 (en) Pharmaceutical compounds
IL249374A0 (en) Pharmaceutical administration forms
IL249130A0 (en) Preparation of piperidine-4-carbthioamide
GB201415811D0 (en) Solid dosage form production
AU358389S (en) Pharmaceutical capsule
PH32014000079S1 (en) Pharmaceutical tablet
GB201502041D0 (en) Solid dosage form production
GB201416969D0 (en) Pharmaceutical compounds
GB201416968D0 (en) Pharmaceutical compounds
GB201416627D0 (en) Pharmaceutical compounds
GB201416622D0 (en) Pharmaceutical compounds
GB201404896D0 (en) Pharmaceutical compounds
GB201402278D0 (en) Pharmaceutical compounds
GB201402013D0 (en) Pharmaceutical compounds
GB201401478D0 (en) Pharmaceutical compounds